Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Tumor cells inhibit myeloid cell phagocytosis and dendritic cell antigen presentation through the novel “Don’t eat me” signal mediated by CLEC-1CLEC-1 represents a new therapeutic target for...
-
Vaccine leverages expertise in peptide selection and optimization and proprietary Memopi® technology to explore a T lymphocyte immune response for COVID-19Uses artificial intelligence algorithm from...
-
Step-1 primary endpoint met: 12-month survival rate in Tedopi® treated patients; Complete analysis of Step-1 results and further discussions with regulatory agencies will determine the best options...
-
Strong clinical progress in lead assets Tedopi®, OSE-127 and BI 765063 Bispecific antibody platform BiCKI®: First project selected, cytokine IL-7 to be paired with anti-PD-1 €5 million milestone...
-
Under this amendment, OSE Immunotherapeutics will receive a €5 million milestone payment at the start of the Sjögren’s Phase 2 study sponsored by Servier, originally scheduled to be part of a...
-
Agreement capitalizes on artificial intelligence and deep learning to develop therapeutic monoclonal antibodies, including novel bispecific antibodies (BiCKI® platform)Collaboration runs for 3 years...
-
NANTES, France, Jan. 14, 2020 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that the Japanese Patent Office has issued a new patent family related to...
-
Planned Phase 2 Studies in Ulcerative Colitis and Sjögren's Syndrome to Start in 2020 NANTES, France, Dec. 02, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE)...
-
NANTES, France and MARSEILLE, France, Nov. 27, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), a clinical-stage biotechnology company focused on developing...
-
NANTES, France, Nov. 11, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), today announced that new clinical and preclinical data on its products in immuno-oncology -...